AR076837A1 - Agentes antiinflamatorios como compuestos virostaticos. - Google Patents
Agentes antiinflamatorios como compuestos virostaticos.Info
- Publication number
- AR076837A1 AR076837A1 ARP100101509A ARP100101509A AR076837A1 AR 076837 A1 AR076837 A1 AR 076837A1 AR P100101509 A ARP100101509 A AR P100101509A AR P100101509 A ARP100101509 A AR P100101509A AR 076837 A1 AR076837 A1 AR 076837A1
- Authority
- AR
- Argentina
- Prior art keywords
- heterocycloalkyl
- alkynylthio
- cycloalkyl
- alkenyl
- alkanyl
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D307/68—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Transplantation (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Reivindicacion 1: Un inhibidor de la dihidroorotato deshidrogenasa caracterizado porque puede usarse en el tratamiento o la mejora de una enfermedad o una condicion médica causadas por una infeccion de virus de ADN de cadena doble (virus de ADNcd), virus de ARN de cadena simple en el sentido positivo (virus de (+)ARNcs), virus de ARN de cadena simple en el sentido negativo (virus de (-)ARNcs), virus de ADN de cadena doble (ADNcd), virus de ARN de cadena simple que usan un intermediario de ADN para replicarse (virus de ARNcs-RT), virus de ADN de cadena doble que usan un intermediario de ARN durante la replicacion del genoma (virus de ADNcd-RT), donde el inhibidor de la dihidroorotato deshidrogenasa no es leflunomida o un metabolito de ésta. Reivindicacion 5: Un inhibidor de la dihidroorotato deshidrogenasa que puede usarse en el tratamiento o la mejora de una enfermedad o una condicion médica causadas por una infeccion viral de acuerdo con cualquiera de las reivindicaciones 1 a 4, caracterizado porque el inhibidor de la dihidroorotato deshidrogenasa es un compuesto de la formula general (1) o un derivado funcional desde el punto de vista fisiologico o una sal tolerable desde el punto de vista farmacologico de éste, donde A es un anillo hidrocarbonado aromático o no aromático de 5 o 6 miembros donde opcionalmente uno o más de los átomos de carbono se reemplazan por un grupo X, donde X se selecciona en forma independiente entre el grupo que consiste en S, O, N, NR4, SO2 y SO; L es una union simple o NH; D es O, S, SO2, NR4, o CH2; Z1 es O, S, o NR5; Z2 es O, S, o NR5; R1 en forma independiente representa H, halogeno, haloalcanilo, haloalquenilo, haloalquinilo, haloalcaniloxi, haloalqueniloxi, haloalquiniloxi, -CO2Rö , -SO3H, -OH, - CONR*Rö, -CRöO, SO2NR*Rö, -NO2, -SO2-Rö, SO-R*, CN, alcaniloxi, alqueniloxi, alquiniloxi, alcaniltio, alqueniltio, alquiniltio, arilo, -NRö-CO2-R', -NRö-CO-R*, -NRö-SO2-R', -O-CO-R*, -O-CO2-R*, -O-CO-NR*Rö; cicloalquilo, heterocicloalquilo, alcanilamino, alquenilamino, alquinilamino, hidroxialcanilamino, hidroxialquenilamino, hidroxialquinilamino, -SH, heteroarilo, alcanilo, alquenilo o alquinilo; R* en forma independiente representa H, alcanilo, alquenilo, alquinilo, cicloalquilo, heterocicloalquilo, aminoalcanilo, aminoalquenilo, aminoalquinilo, alcaniloxi, alqueniloxi, alquiniloxi, -OH, -SH, alcaniltio, alqueniltio, alquiniltio, hidroxialcanilo, hidroxialquenilo, hidroxialquinilo, haloalcanilo, haloalquenilo, haloalquinilo, haloalcaniloxi, haloalqueniloxi, haloalquiniloxi, arilo o heteroarilo; R' en forma independiente representa H, -CO2Rö, -CONRöRö', -CRöO, -SO2NRö, -NRö-CO-haloalcanilo, haloalquenilo, haloalquinilo, -NO2, -NRö -SO2-haloalcanilo, haloalquenilo, haloalquinilo, -NRö-SO2-alcanilo, -NRö-SO2-alquenilo, -NRö-SO2-alquinilo, -SO2-alcanilo, -SO2-alquenilo, -SO2-alquinilo, -NRö-CO-alcanilo, -NRö-CO-alquenilo, -NRö-CO-alquinilo, -CN, alcanilo, alquenilo, alquinilo, cicloalquilo, heterocicloalquilo, aminoalcanilo, aminoalquenilo, aminoalquinilo, alcanilamino, alquenilamino, alquinilamino, alcaniloxi, alqueniloxi, alquiniloxi, -cicloalquiloxi, - OH, -SH, alcaniltio, alqueniltio, alquiniltio, hidroxialcanilo, hidroxialquenilo, hidroxialquinilo, hidroxialcanilamino, hidroxialquenilamino, hidroxialquinilamino, halogeno, haloalcanilo, haloalquenilo, haloalquinilo, haloalcaniloxi, haloalqueniloxi, haloalquiniloxi, arilo, aralquilo o heteroarilo; Rö en forma independiente representa hidrogeno, haloalcanilo, haloalquenilo, haloalquinilo, hidroxialcanilo, hidroxialquenilo, hidroxialquinilo, alcanilo, alquenilo, alquinilo, cicloalquilo, heterocicloalquilo, arilo, heteroarilo, aminoalcanilo, aminoalquenilo o aminoalquinilo; Rö' en forma independiente representa H o alcanilo; R2 es H o OR6, NHR7, NR7OR7; o R2 junto con el átomo de nitrogeno que se une a R8 forma un anillo heterocíclico de entre 5 y 7 miembros, preferentemente de entre 5 y 6 miembros donde R2 es -[CH2]s y R8 se encuentra ausente; R3 es H, alcanilo, alquenilo, alquinilo, cicloalquilo, heterocicloalquilo, arilo, alcaniloxi, alqueniloxi, alquiniloxi, -O-arilo; -O-cicloalquilo, -O-heterocicloalquilo, halogeno, aminoalcanilo, aminoalquenilo, aminoalquinilo, alcanilamino, alquenilamino, alquinilamino, hidroxilamino, hidroxilalcanilo, hidroxilalquenilo, hidroxilalquinilo, haloalcaniloxi, haloalqueniloxi, haloalquiniloxi, heteroarilo, alcaniltio, alqueniltio, alquiniltio, -S-arilo; -S-cicloalquilo, -S-heterocicloalquilo, aralquilo, haloalcanilo, haloalquenilo o haloalquinilo; R4 es H, alcanilo, alquenilo, alquinilo, cicloalquilo, heterocicloalquilo, arilo o heteroarilo; R5 es H, OH, alcaniloxi, alqueniloxi, alquiniloxi, O-arilo, alcanilo, alquenilo, alquinilo o arilo; R6 es H, alcanilo, alquenilo, alquinilo, cicloalquilo, heterocicloalquilo, arilo, heteroarilo, aralquilo, alcaniloxialcanilo, alcaniloxialquenilo, alcaniloxialquinilo, alqueniloxialcanilo, alqueniloxialquenilo, alqueniloxialquinilo, alquiniloxialcanilo, alquiniloxialquenilo, alquiniloxialquinilo, acilalcanilo, (aciloxi)alcanilo, (aciloxi)alquenilo, (aciloxi)alquinilo acilo, (aciloxi)alcanildiéster no simétrico, (aciloxi)alquenildiéster no simétrico, (aciloxi) alquinildiéster no simétrico, o dialcanilfosfato, dialquenilfosfato o dialquinilfosfato; R7 es H, OH, alcanilo, alquenilo, alquinilo, arilo, alcaniloxi, alqueniloxi, alquiniloxi, -O-arilo, cicloalquilo, heterocicloalquilo, o -O-cicloalquilo, -O-heterocicloalquilo; R8 es hidrogeno, alcanilo, alquenilo o alquinilo; E es un grupo alcanilo, alquenilo, alquinilo, arilo, heteroarilo, heterocicloalquilo o cicloalquilo o un sistema de anillos fusionado bicíclico o tricíclico donde un anillo fenilo está fusionado a uno o dos anillos cicloalquilo o heterocicloalquilo monocíclicos o un anillo cicloalquilo o heterocicloalquilo bicíclico, o donde dos anillos fenilo están fusionados a un anillo cicloalquilo o heterocicloalquilo monocíclico, donde los anillos cicloalquilo y heterocicloalquilo monocíclicos y bicíclicos son como se definen en la presente, y donde todos los grupos mencionados pueden estar opcionalmente sustituidos con uno o más sustituyentes R'; Y es hidrogeno, halogeno, haloalcanilo, haloalquenilo, haloalquinilo, haloalcaniloxi, haloalqueniloxi, haloalquiniloxi, alcanilo, alquenilo, alquinilo, arilo, heteroarilo, heterocicloalquilo o cicloalquilo o un sistema de anillos fusionado bicíclico o tricíclico donde un anillo fenilo está fusionado a uno o dos anillos cicloalquilo o heterocicloalquilo monocíclicos o un anillo cicloalquilo o heterocicloalquilo bicíclico, o donde dos anillos fenilo están fusionados a un anillo cicloalquilo o heterocicloalquilo monocíclico, y donde todos los grupos mencionados pueden estar opcionalmente sustituidos con uno o más sustituyentes R', o Y es formula (2) donde R1, X, A, Z1, Z2, R8, R2, E y p son como se definen en la presente; m es 0 o 1; n es 0 o 1; p es 0 o 1; q es 0 o 1; r es 0 o 1; s es entre 0 y 2; y t es entre 0 y 3.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US17525509P | 2009-05-04 | 2009-05-04 | |
EP09159358 | 2009-05-04 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR076837A1 true AR076837A1 (es) | 2011-07-13 |
Family
ID=43030861
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP100101509A AR076837A1 (es) | 2009-05-04 | 2010-05-04 | Agentes antiinflamatorios como compuestos virostaticos. |
Country Status (16)
Country | Link |
---|---|
US (1) | US8354433B2 (es) |
EP (1) | EP2427186B1 (es) |
CN (1) | CN102458389A (es) |
AR (1) | AR076837A1 (es) |
AU (1) | AU2010244462B2 (es) |
CA (1) | CA2761130C (es) |
CO (1) | CO6450622A2 (es) |
ES (1) | ES2909738T3 (es) |
MX (1) | MX2011011733A (es) |
NZ (1) | NZ596014A (es) |
PE (1) | PE20120898A1 (es) |
SG (1) | SG175854A1 (es) |
TW (1) | TWI530286B (es) |
UY (1) | UY32605A (es) |
WO (1) | WO2010128050A2 (es) |
ZA (1) | ZA201108131B (es) |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
UA108760C2 (uk) * | 2010-07-01 | 2015-06-10 | Кальцієві солі сполуки як протизапальні, імуномодулюючі та антипроліферативні засоби | |
WO2013009678A2 (en) * | 2011-07-08 | 2013-01-17 | Indiana University Research And Technology Corporation | Compositions and methods for the treatment of norovirus infection |
AU2014390300A1 (en) * | 2014-04-11 | 2016-10-20 | Panoptes Pharma Gmbh | Anti-inflammatory agents as virostatic compounds |
AU2015257651B2 (en) | 2014-05-08 | 2020-01-23 | Panoptes Pharma Ges.M.B.H. | Compounds for treating ophthalmic diseases and disorders |
WO2018160138A1 (en) | 2017-03-02 | 2018-09-07 | Aslan Pharmaceuticals Pte Ltd | Dhodh inhibitor for treating haematological cancer |
WO2020225330A1 (en) * | 2019-05-07 | 2020-11-12 | Universität Hamburg | Dhodh inhibitors and their use as antiviral agents |
JP2023522245A (ja) * | 2020-04-21 | 2023-05-29 | イミュニック アクチェンゲゼルシャフト | ウイルス性疾患の治療又は予防において使用するためのビドフルジムス |
US20230355602A1 (en) * | 2020-08-31 | 2023-11-09 | Aslan Pharmaceuticals Pte Ltd | Treatment and/or prevention of a viral infection |
WO2022196236A1 (ja) * | 2021-03-18 | 2022-09-22 | 国立大学法人 鹿児島大学 | 抗薬剤耐性インフルエンザウイルス剤及び抗薬剤耐性インフルエンザウイルス剤の製造のための化合物の使用 |
AU2022253683A1 (en) | 2021-04-09 | 2023-10-26 | Immunic Ag | Deuterated dhodh inhibitors |
EP4119138A1 (en) * | 2021-07-12 | 2023-01-18 | Universität Hamburg | Dhodh inhibitors and their use as antiviral agents |
AR128080A1 (es) | 2021-12-23 | 2024-03-20 | Immunic Ag | Inhibidores de dhodh que contienen un bioisóstero de ácido carboxílico |
US20230278979A1 (en) * | 2022-03-01 | 2023-09-07 | Kiora Pharmaceuticals Gmbh | Salts of a dihydroorotate dehydrogenase (dhod) inhibitor |
WO2023172818A1 (en) * | 2022-03-09 | 2023-09-14 | Kiora Pharmaceuticals Gmbh | Polymorphs of a dihydroorotate dehydrogenase (dhod) inhibitor |
WO2023232884A1 (en) | 2022-06-01 | 2023-12-07 | Immunic Ag | Treatment of ulcerative colitis comprising vidofludimus or a pharmaceutically acceptable salt thereof |
CN116803387A (zh) * | 2023-07-25 | 2023-09-26 | 徐州医科大学 | Vidofludimus在制备戊型肝炎药物中的应用 |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE19860802A1 (de) * | 1998-12-30 | 2000-10-26 | Virgene Pharmaceuticals Ag | Herstellung eines Mittels gegen Hepatitis B-, HI-, Paramyxo und Orthomyxo-Viren |
AR025929A1 (es) * | 1999-10-01 | 2002-12-18 | Inst Of Molecul & Cell Biology | Compuestos para el tratamiento de enfermedades mediadas por virus |
MXPA04000224A (es) * | 2001-07-10 | 2005-07-25 | 4Sc Ag | Novedosos compuestos como agentes antiinflamatorios, inmunomoduladores y antiproliferativos. |
US7071355B2 (en) * | 2002-12-23 | 2006-07-04 | 4 Sc Ag | Compounds as anti-inflammatory, immunomodulatory and anti-proliferatory agents |
JP2006511564A (ja) * | 2002-12-23 | 2006-04-06 | 4エスシー エージー | 抗炎症剤、免疫調節剤及び増殖抑制剤としてシクロアルケンジカルボン酸化合物 |
AU2003300530A1 (en) * | 2002-12-23 | 2004-07-14 | 4Sc Ag | Dhodh-inhibitors and method for their identification |
WO2005018330A1 (en) * | 2003-08-18 | 2005-03-03 | Pharmasset, Inc. | Dosing regimen for flaviviridae therapy |
ES2319596B1 (es) | 2006-12-22 | 2010-02-08 | Laboratorios Almirall S.A. | Nuevos derivados de los acidos amino-nicotinico y amino-isonicotinico. |
UY31272A1 (es) | 2007-08-10 | 2009-01-30 | Almirall Lab | Nuevos derivados de ácido azabifenilaminobenzoico |
-
2010
- 2010-04-30 TW TW099113936A patent/TWI530286B/zh not_active IP Right Cessation
- 2010-05-03 US US12/772,470 patent/US8354433B2/en active Active
- 2010-05-03 UY UY0001032605A patent/UY32605A/es not_active Application Discontinuation
- 2010-05-04 CA CA2761130A patent/CA2761130C/en not_active Expired - Fee Related
- 2010-05-04 PE PE2011001900A patent/PE20120898A1/es not_active Application Discontinuation
- 2010-05-04 WO PCT/EP2010/056042 patent/WO2010128050A2/en active Application Filing
- 2010-05-04 AU AU2010244462A patent/AU2010244462B2/en not_active Ceased
- 2010-05-04 NZ NZ596014A patent/NZ596014A/xx not_active IP Right Cessation
- 2010-05-04 AR ARP100101509A patent/AR076837A1/es unknown
- 2010-05-04 SG SG2011080488A patent/SG175854A1/en unknown
- 2010-05-04 CN CN2010800290606A patent/CN102458389A/zh active Pending
- 2010-05-04 MX MX2011011733A patent/MX2011011733A/es active IP Right Grant
- 2010-05-04 EP EP10715894.1A patent/EP2427186B1/en active Active
- 2010-05-04 ES ES10715894T patent/ES2909738T3/es active Active
-
2011
- 2011-11-03 ZA ZA2011/08131A patent/ZA201108131B/en unknown
- 2011-11-04 CO CO11150236A patent/CO6450622A2/es not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
WO2010128050A2 (en) | 2010-11-11 |
PE20120898A1 (es) | 2012-08-24 |
US20100280081A1 (en) | 2010-11-04 |
AU2010244462A1 (en) | 2011-11-17 |
CA2761130C (en) | 2017-03-28 |
SG175854A1 (en) | 2011-12-29 |
AU2010244462B2 (en) | 2015-07-02 |
US8354433B2 (en) | 2013-01-15 |
ES2909738T3 (es) | 2022-05-10 |
EP2427186A2 (en) | 2012-03-14 |
MX2011011733A (es) | 2012-02-01 |
TW201043228A (en) | 2010-12-16 |
NZ596014A (en) | 2013-06-28 |
WO2010128050A3 (en) | 2011-05-05 |
TWI530286B (zh) | 2016-04-21 |
CO6450622A2 (es) | 2012-05-31 |
CA2761130A1 (en) | 2010-11-11 |
ZA201108131B (en) | 2012-07-25 |
UY32605A (es) | 2010-12-31 |
CN102458389A (zh) | 2012-05-16 |
EP2427186B1 (en) | 2022-01-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR076837A1 (es) | Agentes antiinflamatorios como compuestos virostaticos. | |
CY1118969T1 (el) | Ενωσεις πυριμιδινο-2-αμινης και η χρηση τους ως αναστολεις των κινασων jak | |
AR082937A1 (es) | Fosforamidatos de nucleosido | |
CY1118102T1 (el) | Αλατα διαμινιου φαινοθειαζινης και η χρηση αυτων | |
EA200900154A1 (ru) | Фосфинатные соединения (варианты), фармацевтическая композиция на их основе, способ лечения вирусного гепатита с с ее помощью, терапевтическое средство на их основе и названные соединения для изготовления лекарства от вирусного гепатита с | |
PE20131165A1 (es) | Analogos de carba-nucleosidos sustituidos con 2'-fluoro para tratamiento antiviral | |
RU2011124304A (ru) | Ингибиторы протеинкиназ (варианты), их применение для лечения онкологических заболеваний и фармацевтическая композиция на их основе | |
DOP2013000238A (es) | Derivados de nucleosidos 2'-sustituidos y metodos de uso de los mismos para el tratamiento de enfermedades virales | |
EA201001508A1 (ru) | Мостиковые гетероциклические соединения в качестве ингибиторов интегразы вич | |
CY1114647T1 (el) | Παραγωγο (αζα)και χρηση αυτου για ιατρικους σκοπους | |
RU2014143250A (ru) | Производные 7-оксо-тиазолопиридин карбоновой кислоты и их применение при лечении, облегчении или профилактике вирусного заболевания | |
CY1124197T1 (el) | Antinohmatika πολυνουκλεοτιδια για να διεγειρεται παραλειψη εξονιου και μεθοδοι θεραπειας δυστροφιων | |
JP2016518305A5 (es) | ||
EA201491179A1 (ru) | 2',4'-дифтор-2'-метил замещенные нуклеозидные производные в качестве ингибиторов репликации рнк вируса гепатита с | |
EA201491180A1 (ru) | 4'-азидо,3'-фторзамещенные производные нуклеозидов в качестве ингибиторов репликации рнк вируса гепатита с | |
EA201000100A1 (ru) | Гетероциклические соединения, полезные в качестве ингибиторов mk2 | |
AR084976A1 (es) | Compuestos de bifenileno sustituidos y metodos de uso de los mismos para el tratamiento de enfermedades virales | |
BR112015021336A2 (pt) | compostos 1,3-oxazin-2-amina fundidos ciclopropil perfluorados como inibidores de beta-secretase e métodos de uso | |
JP2015517555A5 (es) | ||
EA201391264A1 (ru) | 1'-замещенные пиримидиновые n-нуклеозидные аналоги для противовирусного лечения | |
EA200702339A1 (ru) | Замещенные амидные производные в качестве ингибиторов протеинкиназы | |
JP2015521189A5 (es) | ||
BR112013009029A2 (pt) | métodos e composições para inibição de polimerase | |
BRPI0408591A (pt) | derivados de 6,7,8,9-tetrahidropirimido[1,2-a] pirimidin-4-ona 8-substituìda | |
EA201201277A1 (ru) | Кристаллические соли эффективного ингибитора вируса гепатита с |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |